The global chronic heart failure (CHF) therapeutics market has been forecast to grow at a compound annual growth rate (CAGR) of 3.1% over the next eight years, to reach a market value of $4,918.4 million by 2019.
This is a slightly smaller CAGR than the one recorded between 2006 and 2011, when the market grew at a CAGR of 4% from $3,171.3 million in 2006 to $3,849.9 million in 2011.
Growth within the CHF therapeutics market is expected to grow due to greater health awareness among the general public, increased life expectancy and, consequently, an aging global population, which will be naturally more susceptible to acute heart failure (AHF).
Currently, the only treatment choices available to the CHF therapeutics market are generic drugs, which do not treat the underlying cause of the disease. Drugs such as beta-blockers and diuretics can manage the symptoms of CHF by improving cardiac function, but none can provide disease-modifying mechanisms.
As a result, demand is growing for new treatment options that can present improved safety and efficacy and unique new molecules that can restore or regenerate impaired cardiac muscle cells.
Various pipeline molecules are expected to enter the market within the next few years to provide improved options for CHF patients. Our analysis shows that there are 41 molecules under development in the CHF therapeutics pipeline, of which 78% are First-in-Class (FIC) and 25% are in Phase III.
For more information on the global chronic heart failure therapeutics market, see the latest research: Chronic Heart Failure Therapeutics Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.